NCT00149422已完成不适用
Can Pro-brain-natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?
Netherlands Heart Foundation2 个研究点 分布在 1 个国家开始时间: 2004年6月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 2
- 主要终点
- Difference in total number of days alive and outside the hospital between the NT-proBNP guided and the clinical guided group.
研究概览
简要总结
The purpose of this study is to determine whether NT-proBNP guided treatment of chronic congestive heart failure will reduce heart failure related morbidity and mortality compared to therapy guided by standard clinical judgement.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Single
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Admission because of congestive heart failure
- •Elevated NT-proBNP levels on admission
排除标准
- •Life-threatening cardiac arrhythmias
- •Urgent intervention
- •Severe lung disease
- •Presence of life threatening disease
- •Signed informed consent for other study
- •Mental or physical status not allowing written informed consent.
- •Unwillingness to give informed consent
- •Patients undergoing haemodialysis or continuous ambulatory peritoneal dialysis (CAPD)
结局指标
主要结局
Difference in total number of days alive and outside the hospital between the NT-proBNP guided and the clinical guided group.
时间窗: minimum of one year
次要结局
- Differences in primary and secondary outcome measures among renal function and age subgroups(At least one year)
- Differences in evidence based heart failure medication prescription after 3, 6 and 12 months(At least one year)
- Analysis of major endpoints in patients where NT-proBNP levels were at or below the individual target level in at least 75% of all outpatient visits(at least one year)
- All cause mortality(at least one year)
- Cardiovascular mortality(at least one year)
- All cause hospitalization(at least one year)
- Cardiovascular related hospitalization(at least one year)
- Total number of hospitalizations and mortality(at least one year)
- Total number of cardiovascular hospitalizations and mortality(at least one year)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Study of NT-proBNP Combined With HS-cTnT in Evaluating the Prognosis of SepsisSepsisNCT04963699Second Affiliated Hospital, School of Medicine, Zhejiang University80
终止
3 期
Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways DiseaseHeart FailureNCT00562692The Alfred6
已完成
不适用
Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting.Congestive Heart FailureNCT00351390Massachusetts General Hospital152
进行中（未招募）
1 期
Therapeutic effects of a cardiac hormone, named BNP, in patients with poorly controlled high levels of blood pressurencontrolled hypertension (UHT, i.e. blood pressure = 150/90, or = 150/85 mm Hg in diabetic patients) despite treatment with at least twodifferent classes of antihypertensive medications.EUCTR2015-000577-13-NOOslo University Hospital15
Unknown
不适用
NT-proBNP Measurements to Rule-out Heart Failure Among Patients With Atrial Fibrillation: A Prospective Clinical StudyHeart FailureAtrial FibrillationNCT04125966University of Aarhus403